Ginsana-115

AssetAlso Ginsena-115, Ginsana

Modulates NLRP3 inflammasome activation and GLP-1 release to improve inflammatory and metabolic signaling.

Stage: Human trials
Modality: Supplement
Target: NLRP3; 3
Indications: 0
Trials: 1
Developer

Indications

3

Cardiovascular disease prevention
Human trials, doi.org, 5 Jun 2026
Treatment-resistant schizophrenia
Human trials, doi.org, 5 Jun 2026
Type 2 diabetes prevention
Human trials, doi.org, 5 Jun 2026

In the full profile

Targets and what it contains3
Owner and partners1
Evidence for its targets4
Competitors11
Aging relevance1
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.